Wellesta and MitrAssist Lifesciences have strengthened their partnership to market and distribute the ReDS™ Pro (Remote Dielectric Sensing) system in Austria, Belgium, France, the Netherlands, Poland, and Switzerland.

With this expanded agreement, Wellesta Europe now holds exclusive rights to commercialize ReDS™ Pro — an innovative, non-invasive technology developed by Sensible Medical Innovations (Netanya, Israel). FDA and CE-approved, ReDS™ Pro enables precise, real-time monitoring of lung fluid levels, offering clinicians critical insights for the management of heart failure and other fluid-related conditions.

ReDS™ Pro is utilized across the entire continuum of care – from hospital wards and outpatient clinics to post-acute facilities and remote patient monitoring at home. This empowers healthcare providers to make timely, informed decisions that reduce hospital readmissions and improve patient outcomes.


Peggy Wang, Chairperson of MitrAssist Lifesciences, is excited about extending the benefits of ReDS™ Pro to new geographies.

“We are happy to expand our collaboration with Wellesta to bring ReDS™ Pro to additional European regions. With Wellesta’s established market presence and trusted reputation, we are confident that clinicians will benefit from this fast, reliable, and user-friendly tool to assess pulmonary congestion – a key factor in managing heart failure effectively.”

Milan Paleja, Chairman & Managing Director of Wellesta, added:

“ReDS™ is already transforming care in hospitals, emergency departments, and home settings by helping cardiologists and heart failure teams manage fluid status more effectively. Through this strategic expansion, we aim to support healthcare professionals across Europe in improving clinical outcomes and enhancing the quality of life for patients.”

To this, Dr. Beat Sümegi, Regional Head/Managing Director of Wellesta Europe said,

“Expanding access to ReDS™ Pro across the six European countries marks a pivotal step in advancing heart failure care. With its rapid, non-invasive lung fluid monitoring, the system equips clinicians with precise data to make faster, more confident treatment decisions. Our strengthened partnership with MitrAssist Lifesciences underscores our shared commitment to delivering clinically impactful innovations that reduce hospitalizations and enhance patients’ quality of life. We are excited to support healthcare providers across Europe in adopting this groundbreaking technology.”

About Wellesta:

Wellesta Holdings Pte Ltd is a healthcare company headquartered in Singapore with a direct market presence in Southeast Asia, India & Europe and partnering in MENA. We aim to serve clients and consumers through commercial and marketing support using an innovative approach across the Wellesta value chain. We work with companies to expand their presence in our operating regions, as a strategic partner for companies present in these markets and act as a representative for companies that are not present in these markets and would like to sell/market their products in the region.

Wellesta Holdings operate in a spectrum of business verticals under partner brands and own brands including pharmaceutical, nutraceuticals, OTC and medical devices, led by industry-proven leaders at HQ & Country level. Wellesta works as an extended arm for our principals through win-win partnership and provides superior quality products and services at the right price, by working at full compliance and transparency in our business approach.

For further information, visit: http://www.wellesta.com and our LinkedIn page.

About MitrAssist Lifesciences:

Founded in 2017, MitrAssist Lifesciences Ltd is a leading global platform company dedicated to innovative cardiovascular medical devices. The company focuses on providing advanced diagnostic and therapeutic solutions to improve outcomes for patients with cardiovascular diseases.

As a pioneer in the cardiovascular field, MitrAssist Lifesciences Ltd promotes technological innovation, with a product portfolio spanning diagnosis, prognosis, treatment and surgery – providing systematic, multi-disease solutions for comprehensive cardiovascular care.

Its offerings in heart failure, structural heart disease and drug-coated balloon technologies address both cardiology and cardiac surgery, enabling a high degree of focus and synergy across the care continuum.

For further information, visit: https://www.mitrassist.com.cn/ and our LinkedIn page.

Dr. Beat Sumegi has been appointed as Regional Head/Managing Director of Wellesta Group for Europe business. Prior to joining Wellesta, he was the Global Head for Medical Excellence & Operations for Galderma S.A, Switzerland.

Dr. Beat is a seasoned Medical & Business leader with close to 30 years of extensive experience in the Pharma industry. He started his career as a Physician for 4 years in Austria, S. Africa and Switzerland. Later he held various leadership roles across different cultures and geographies in Medical Affairs, R&D and Commercial with expertise in General Management, Board-level interaction, Commercial Strategy, Sales & Marketing, Market Access, Medical Affairs, Digital Innovation.

He is a patient-centric Senior Pharma Executive, successfully leveraging his experience as accomplished physician in strategic & operational roles across different pharmaceutical divisions in mature and emerging markets. With 22 years of experience in Novartis, he successfully developed, launched, and expanded primary care and specialty medicines across various therapeutic areas.

Dr. Beat joined Sanofi, Paris as Global Head of Medical Operations & Effectiveness, SVP in 2017 and later moved to Galderma, Switzerland as a Global Head for Medical Excellence & Operations. Throughout his career as a Medical leader, he established and led impactful and highly efficient medical organizations (global, regional and local) and pioneered the integration of digital technology & AI in engagement strategies.

Dr. Beat Sümegi holds an Executive master’s degree in business administration from Concordia University, Faculty of Commerce, John Molson School of Business, Montréal, Canada, and a Medical Doctor’s degree from University of Vienna, Faculty of Medicine, Vienna, Austria. He is a certified Physician in Austria and EU, Switzerland, and South Africa.

We at Wellesta start our foot print in Europe with appointment of Dr Beat , who will lead work in areas of In Licencing, Out licensing & also Business development work for IntelliMedEsta, our medical services arm. We are sure that Dr. Beat Sümegi’s experience and leadership will help achieve our vision and mission in Europe. He will report to Mr. Milan Paleja, Chairman and MD of Wellesta Group.

We welcome Dr. Beat Sumegi to the Wellesta family and wish him great success in this new position.